drugset / Trial / NCT00261053
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this single-center study is to explore the efficacy, safety, tolerability and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute attacks in patients with hereditary angioedema.
Timeline
- Start
- 2003-06
- Primary completion
- 2005-09
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | recombinant human C1 inhibitor | Protein / enzyme biologic | 100 iu/kg | Intravenous |